Is Healthcare Global Enterprises Ltd (HCG) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Healthcare Global Enterprises Ltd is a average quality company .

Is Healthcare Global Enterprises Ltd (HCG) undervalued or overvalued?

The key valuation ratios of Healthcare Global Enterprises Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Healthcare Global Enterprises Ltd (HCG) share price return in the past 10 years?

Healthcare Global Enterprises Ltd share price has appreciated 12.3% annually (CAGR) over the past ten years.

Is Healthcare Global Enterprises Ltd (HCG) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Healthcare Global Enterprises Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Healthcare Global Enterprises Ltd (HCG)?

Company share prices are keep on changing according to the market conditions. The current trading price of Healthcare Global Enterprises Ltd (HCG) on 30-Apr-2026 16:59:59 at 16:59 is 572.55.

What is the P/E ratio of Healthcare Global Enterprises?

The latest standalone P/E ratio of Healthcare Global Enterprises as of 30-Apr-2026 is 368.46.

What is the P/B ratio of Healthcare Global Enterprises Ltd (HCG)?

The latest standalone P/B ratio of Healthcare Global Enterprises Ltd (HCG) as of 30-Apr-2026 is 5.32.

What is the 52-week high and low of Healthcare Global Enterprises Ltd (HCG)?

The 52-week high of Healthcare Global Enterprises Ltd (HCG) is Rs. 799.36 and the 52-week low is Rs. 511.83.

Healthcare Global Enterprises Ltd (HCG) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Healthcare Global Enterprises Ltd (HCG)
Brand: Healthcare Global Enterprises

Key Metrics

Market Cap

₹8,548 Cr.

P/E Ratio

368.46

Price to Book (P/B)

5.32

Price to Sales (P/S)

6.39

EV/EBITDA

36.02

Return on Capital Employed (ROCE)

6.03%

Current Price

₹572.6

Return on Equity (ROE)

0.30%

Return on Assets (ROA)

0.15%

Operating Profit Margin

16.6%

Net Profit Margin

0.28%

Gross Profit Margin

13%

Book Value per Share

₹107.7

Sales Growth (YoY)

9.04%

Sales Growth (3 Years)

14.52%

Operating Profit Growth (1 Year)

5.36%

Operating Profit Growth (3 Years)

12.9%

Net Profit Growth (1 Year)

-89.24%

52-Week Low / High

₹512 / 799

Net Profit Growth (3 Years)

-54.82%

Dividend Yield

0.00%

Promoter Holding

64.21%

Pledged shares (%)
of Promoter's holding (%)

5.17%

Check Before You Invest

Q.1 Stock return of Healthcare Global Enterprises Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 12.3% based on the current price.

Q.1 Revenue growth of Healthcare Global Enterprises Ltd?

Healthcare Global Enterprises Ltd revenue growth is 9% for FY-2025, which is below its 5-year CAGR of 13.15%, indicating slower growth.

Q.1 Which industry/sub-sector does Healthcare Global Enterprises Ltd belong to?

Healthcare Global Enterprises Ltd belongs to the Healthcare sector, operating specifically within the Hospital & Healthcare Services segment.

Q.1 Promoter shareholding and pledge status of Healthcare Global Enterprises Ltd?

Promoters hold 64.21% of the Healthcare Global Enterprises Ltd, with 5.17% of their stake pledged, indicating low pledge risk.

Q.1 Revenue growth of Healthcare Global Enterprises Ltd vs industry peers?

Healthcare Global Enterprises Ltd revenue CAGR is 13.15%, compared to the industry median CAGR of 10.30%, indicating faster growth and gaining its market share.

DeciZen - make an informed investing decision on HealthcareGlobal

Based on:

Data
Research

Standalone basis

1. Right Stock

2. Right Price

Price Chart

3. Right Time ⓘ

#Likely Future 5 Year CAGR.

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation

3. Price Trend

Healthcare Global Enterprises stock performance

Key Ratios

Is Healthcare Global Enterprises Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	4%	6.1%	7.7%	6.1%	1.6%	-12.6%	10.5%	8%	7.3%	6%	-
Value Creation Index ⓘ	-0.7	-0.6	-0.5	-0.6	-0.9	-1.9	-0.3	-0.4	-0.5	-0.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	471	545	586	641	688	609	850	1,006	1,171	1,277	1,338
Sales YoY Gr.	-	15.7%	7.6%	9.3%	7.5%	-11.6%	39.6%	18.3%	16.4%	9%	-
Adj EPS ⓘ	-0.2	2.2	2	0.8	-6.1	-15.2	0.1	3.1	3.1	2	1.6
YoY Gr.	-	NA	-11.2%	-60.8%	-878.2%	NA	NA	4271.4%	1.3%	-36.1%	-
BVPS (₹) ⓘ	60.6	63.1	69.2	72.3	68.1	69.2	78	81	83.1	83.3	107.7
Adj Net Profit ⓘ	-1.8	19.3	17.4	6.9	-54.2	-192	1	42.8	43.4	27.8	23
Cash Flow from Ops. ⓘ	57.8	53.9	66.4	87	86.3	70.9	124	130	209	146	-
Debt/CF from Ops. ⓘ	3.4	4	4	4.9	5.7	3.4	0.9	0.9	2	4.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	11.7%	13.2%	14.5%	9%
Adj EPS ⓘ	NA	NA	204.7%	-36.1%
BVPSⓘ	3.6%	4.1%	2.2%	0.3%
Share Price	12.3%	26.7%	28.7%	0.7%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-0.5	3.6	2.9	1.1	-8.6	-24.9	0.1	3.8	3.7	2.3	1.6
Op. Profit Mgn % ⓘ	13.6	15.2	14	14.7	16.8	12.1	17.3	16.9	17.1	16.6	16.8
Net Profit Mgn % ⓘ	-0.4	3.5	3	1.1	-7.9	-31.5	0.1	4.3	3.7	2.2	1.7
Debt to Equity ⓘ	0.4	0.4	0.4	0.7	0.8	0.3	0.1	0.1	0.4	0.6	-
Working Cap Days ⓘ	128	130	161	211	240	257	150	124	134	153	80
Cash Conv. Cycle ⓘ	-18	-16	-3	10	22	38	26	26	22	21	-0

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	1.6	1.3
TTM Sales (₹ Cr.)	1,338	2,477
BVPS (₹) ⓘ	107.7	89.6
Reserves (₹ Cr.) ⓘ	1,458	1,188
P/BV ⓘ	5.32	6.39
PE ⓘ	368.46	451.10

From the Market
52 Week Low / High (₹)	511.83 / 799.36
All Time Low / High (₹)	62.56 / 799.36
Market Cap (₹ Cr.)	8,548
Equity (₹ Cr.)	149.3
Face Value (₹)	10
Industry PE ⓘ	86.9

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

3.09

4.99

5.70

5.52

5.17

* Pledged shares as % of Promoter's holding (%)

Valuation of HealthcareGlobal - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	471	545	586	640	688	609	850	1,006	1,171	1,277
Operating Expenses ⓘ +	407	462	504	546	573	535	703	837	970	1,065
Manufacturing Costs	141	158	159	192	215	196	241	273	312	350
Material Costs	134	149	155	153	147	138	210	236	281	318
Employee Cost	85	98	116	130	143	137	157	175	205	221
Other Costs ⓘ	48	57	75	71	69	65	95	153	171	177
Operating Profit ⓘ	64	83	82	94	116	73	147	169	201	211
Operating Profit Margin (%)	13.5%	15.2%	13.9%	14.7%	16.8%	12.1%	17.3%	16.8%	17.1%	16.6%
Other Income ⓘ +	3	7	23	13	12	24	12	22	16	39
Exceptional Items ⓘ	-4	0	3	0	-31	-153	53	-3	-16	-35
Interest ⓘ	34	16	27	48	83	63	43	41	50	84
Depreciation ⓘ	37	44	44	47	79	87	88	89	97	111
Profit Before Tax ⓘ	-9	29	37	13	-65	-205	81	58	54	20
Tax ⓘ	-4	10	12	5	-12	-14	43	17	21	16
Profit After Tax	-5	19	25	7	-53	-192	38	40	33	4
PAT Margin (%)	-1.0%	3.6%	4.3%	1.1%	-7.7%	-31.5%	4.5%	4.0%	2.8%	0.3%
Adjusted EPS (₹)	-0.6	2.3	2.9	0.8	-6.0	-15.2	2.7	2.9	2.3	0.3
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	519	544	605	639	607	873	1,091	1,133	1,164	1,169
Share Capital ⓘ	85	86	87	88	89	125	139	139	139	139
Reserves ⓘ	434	458	518	551	519	748	952	994	1,025	1,030
Debt +	160	165	219	396	419	214	83	113	375	583
Long Term Debt	123	124	217	346	315	147	82	113	274	304
Short Term Debt	37	41	2	50	104	67	1	0	101	280
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	97	105	114	106	99	81	96	109	148	152
Others Liabilities ⓘ	60	96	165	259	628	379	374	375	552	699
Total Liabilities ⓘ	836	910	1,103	1,400	1,754	1,547	1,644	1,730	2,239	2,604
Fixed Assets
Net Fixed Assets ⓘ +	431	442	492	547	914	745	774	788	974	1,038
Gross Block	467	511	591	693	1,141	1,058	1,177	1,275	1,566	1,699
Accumulated Depreciation	36	69	99	146	227	313	403	487	592	661
CWIP ⓘ	29	33	79	104	44	28	5	9	36	23
Investments ⓘ	155	141	219	299	316	366	439	475	506	696
Inventories	11	15	17	16	13	12	17	21	23	20
Trade Receivables	69	101	126	146	152	147	160	212	221	262
Cash Equivalents	50	75	15	9	15	14	120	80	237	264
Others Assets ⓘ	91	103	155	280	300	235	129	144	241	302
Total Assets ⓘ	836	910	1,103	1,400	1,754	1,547	1,644	1,730	2,239	2,604

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	58	54	66	87	86	71	124	130	209	146
PBT ⓘ	-9	29	37	13	-65	-205	81	58	54	20
Adjustment ⓘ	74	57	60	91	192	285	79	150	174	227
Changes in Working Capital ⓘ	-0	-25	-32	10	-20	-49	-21	-60	14	-82
Tax Paid ⓘ	-8	-7	1	-26	-20	40	-15	-17	-33	-19
Cash Flow From Investing Activity ⓘ +	-86	-73	-185	-208	-116	-246	49	-138	-254	-347
Capex	-90	-40	-104	-123	-80	-23	-42	-95	-129	-33
Net Investments	-3	2	20	-15	4	-102	189	-10	-47	-112
Others ⓘ	7	-35	-100	-70	-40	-120	-99	-32	-78	-202
Cash Flow From Financing Activity ⓘ +	120	-14	91	66	-3	236	-41	-42	96	-42
Net Proceeds from Shares ⓘ	271	7	35	0	20	453	132	1	2	2
Net Proceeds from Borrowing ⓘ	-110	-9	79	106	36	-219	-67	14	167	57
Interest Paid ⓘ	-33	-12	-23	-40	-66	-59	-43	-36	-48	-90
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-8	0	0	0	7	62	-63	-21	-25	-10
Net Cash Flow ⓘ	92	-33	-27	-55	-32	61	132	-49	51	-243

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-1.2	3.67	4.33	1.16	-8.55	-25.87	3.9	3.61	2.86	0.3
ROCE (%)	3.98	6.12	7.65	6.13	1.62	-12.55	10.46	8.02	7.25	6.03
Asset Turnover Ratio	0.62	0.62	0.58	0.51	0.44	0.37	0.53	0.6	0.59	0.53
PAT to CFO Conversion(x)	N/A	2.84	2.64	12.43	N/A	N/A	3.26	3.25	6.33	36.5
Working Capital Days
Receivable Days	51.70	56.80	70.60	77.50	79	89.90	66.10	67.60	67.50	69
Inventory Days	9.30	8.70	10	9.50	7.70	7.30	6.30	7	6.90	6.10
Payable Days	235.10	247.60	258.50	262.80	255.80	237.80	154.10	158.60	166.60	172.40

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Healthcare Global Enterprises Ltd FAQs

The current trading price of HealthcareGlobal on 30-Apr-2026 16:59 is ₹572.5.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Apr-2026 the market cap of HealthcareGlobal stood at ₹8,548.3 Cr

The latest P/E ratio of HealthcareGlobal as of 29-Apr-2026 is 368.5.

The latest P/B ratio of HealthcareGlobal as of 29-Apr-2026 is 5.32.

The 52-week high of HealthcareGlobal is ₹799.4 and the 52-week low is ₹511.8.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of HealthcareGlobal is ₹1,338 ( Cr.) .

About Healthcare Global Enterprises Ltd

HealthCare Global Enterprises (HCG), founded in 1989, offers cancer care, tertiary care, infertility treatment, and advanced screening and diagnostic services. HCG has four entities: HCG - the Specialist in Cancer Care, HCG Hospitals - for Multispecialty Care, Milann - the Fertility Center, and Triesta Sciences - the Diagnostic Center. Strategically positioned throughout South Asia and Africa, these entities offer comprehensive healthcare services to patients from diverse backgrounds worldwide.

The company has a robust network of specialists, including oncologists, experienced doctors, and visiting doctors, all dedicated to providing individualized and patient-focused care. In India, HCG has many centers, which include comprehensive cancer hospitals, multispeciality hospitals, and day care chemotherapy centers spanning across metropolitan, tier II, and tier III cities. Apart from its centers in India, HCG has a comprehensive cancer center in Nairobi, Kenya (HCG - Cancer Care Kenya) to cater to the cancer care needs of the African population.

The company was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a private limited company under the Companies Act, 1956. The name of the company was subsequently changed to HealthCare Global Enterprises Private Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on November 14, 2005. The company was converted into a public limited company pursuant to a special resolution passed by its Shareholders at the extraordinary general meeting held on May 20, 2006 and the name of the company was changed to HealthCare Global Enterprises Limited. A fresh certificate of incorporation consequent upon conversion to a public limited company was issued by the RoC on July 5, 2006.

Business area of the company

The company is a leading healthcare provider in India dedicated to delivering patient-centric and personalized care for cancer and other health conditions. With over years of experience in the healthcare space, the company helped millions of patients receive comprehensive care and support and return to the best state of health possible.

Awards

2015: At Frost and Sullivan 7th Annual Indian Healthcare Excellence Awards in 2015, Milann was recognised as the 'Emerging IVF Service Provider Company of the Year'.
2016: The HCG network was ranked second in India and first in the South India region and Bengaluru for cancer care in the Times Health All India Critical Care Hospital Ranking Survey 2016.
2018: HCG Hospitals, Bhavnagar was recognised as the 'Best Multispeciality Hospital' in Bhavnagar by Saurashtra Samachar in 2018.
2018: HCG Cancer Centre, Ahmedabad was awarded as the 'Best Cancer Hospital' by DivyaBhaskar in 2018.
2019: Milann has been honoured with The National Icon Award 2018-19 for being 'India's Most Trusted IVF Centre'.
2021: HCG Cancer Hospital Bengaluru bestowed with the 'Nursing Excellence' award at the Association of Healthcare Providers - India (AHPI) Award 2021.
2021: Three centres from the HCG network, namely Bangalore, Mumbai and Vadodara bagged 1st, 3rd and 6th positions under the National Single Speciality
2021: Oncology category in the Times Health's All India Critical Care Hospital - Ranking Survey 2021.
2021: Milann has been recognised as 'The Best Fertility and IVF Chain in India' by ET Healthcare Brands.
2021: HCG Cancer Centre, Ahmedabad, has been honoured with the Times Healthcare Leaders Ahmedabad 2021 Awards for 'Excellence in Oncology' and 'Excellence in Innovative Technology'.
2021: HCG Cancer Centre, Ahmedabad, was ranked amongst the World's Best Hospitals 2021 by Newsweek Magazine.
2022: HCG Cancer Centre, Vadodara bestowed by 'Eminence Award 2022' by Divya Bhaskar
2022: HCG bestowed with BW HealthcareWorld Excellence Awards '22 under the Institutional Excellence in Oncology category for outstanding contributions to healthcare.
2022: HCG Hospitals Bhavnagar awarded for exemplary performance under Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB PM-JAY)
2022: HCG Hospitals Bhavnagar Ranked 1st in the competition of Swachh Hospitals between Hospitals of Bhavnagar City during 'Swachh Survekshan - 2022' held by Solid Waste Management System, Bhavnagar Municipal Corporation
2022: HCG Cancer Centre Ahmedabad received Certificate of appreciation from Ahmedabad Municipal Corporation for commendable work in ABPMJAY
2022: HCG Cancer Centre Ahmedabad received Certificate of Recognition by Times Healthcare Leaders for excellence in Patient Care & Safety
2022: HCG Cancer Centre Ahmedabad bestowed with Certificate of Recognition by Times Healthcare for most Promising Brand in Comprehensive Ortho Care
2022: HCG Cancer Centre Ahmedabad has been honoured with Gold Category award from Government of Gujarat in recognition of adherence to the Quality Certification standards of AB PM-JAY
2023: 7th NURSING CONCLAVE; 28 June: Confederation of Indian Industry (CII) and Indian Women Network (IWN) organized Joyee 2023. Recognition of Excellence in Nursing - a felicitation program for care givers at the sideline of 7th Nursing Conclave to acknowledge the exceptional contribution made by the nurses from the hospitals of the region.
2023: HCG Abdur Razzaque Ansari Cancer Hospital Ranchi is ranked 16th in All India Critical Care Hospital Ranking Survey 2023 by The Times of India under the category - 'Best National Single Specialty in Oncology'.
2023: HCG Cancer Centre Nagpur was conferred with Navabharat Health Excellence Award 2023 under the best cancer hospital category.
2023: HCG Cancer Centre Nagpur awarded Vidarbh Ratna Award 2023 under the best cancer hospital category for excellence in different sectors where we stood on top in healthcare.
2024: BW Healthcare Excellence Awards '2024 under the Institutional Excellence in Oncology
2024: Healthcare Global Enterprises Ltd (HCG) has been recognized as the ESG (Environmental, Social, and Governance) Champion of India 2024 at the prestigious Dun & Bradstreet 'ESG Leadership Summit 2024.' This accolade is a testament to our constant commitment to sustainability, social responsibility, and ethical governance practices
2025: HCG Cancer Hospital, Nagpur, was recognized as the 5th Best Oncology Setup in the West Region in The Week – Hansa Research Best Hospitals Survey.
2025: HCG Cancer Hospital, Nagpur, received the Best Cancer Centre in Central India Award at the Navabharat Healthcare Summit 2025.
2025: HCG Cancer Hospital, Nagpur, was honored by the Sakal Media Group for Excellence in Oncology Care at the Sakal Arogya Coffee Table Book event.
2025: HCG Cancer Centre, Borivali, has been honored with the Excellence Award in the category of Oncology & Cancer Care at the Radio City Mumbai Icon Awards 2025
2025: HCG Cancer Centre, Borivali, has been ranked No. 1 in the Western Suburbs for Oncology by Mid-Day.
2025: HCG ICS Khubhchandani Cancer Centre has been honored with the Excellence Award in the category of Oncology & Cancer Care at the Radio City Mumbai Icon Awards 2025.
2025: The Mid-Day Critical Care Hospital Survey 2025 recognized HCG ICS Khubchandani Cancer Centre as the 2nd Best Hospital for Oncology in Mumbai.
2025: HCG ICS Khubhchandani Cancer Centre earned the Excellence in Cancer Care & Innovation distinction at the Times Healthcare Leaders Awards 2025.
2025: HCG ICS Khubhchandani Cancer Centre has received recognition for Excellence in Precision Cancer Treatment at the Times Healthcare Leaders Awards 2025.
2025: HCG ICS Khubhchandani Cancer Centre has been awarded Best Cancer Institute in Mumbai at the Navbharat Times Awards 2025.
2026: HCG Cancer Hospital, Borivali, has been recognized as the Center of Excellence in Comprehensive Cancer Care 2025–26 by Corporate Connect.

Milestones

1989: Bangalore Institute of Oncology commences operation.
1998: Company incorporated as Curie Centre of Oncology.
2005: Company’s name changed to HealthCare Global Enterprises Pvt. Ltd.
2005: Entry into clinical laboratory business through acquisition of Triesta Sciences.
2006: 1st to introduce IGRT technology in North India.
2006: Acquired the 1st privately owned comprehensive cancer care centre in Karnataka.
2006: 1st private cancer centre in India to introduce Cyclotron and PET-CT.
2006: India Development Fund made its first investment of Rs 500 million in the company.
2006: BMORCL became its subsidiary.
2007: HCG Medi-Surge became its subsidiary.
2007: Evolvence made its first investment of Rs 225 million in the company,
2008: NTICPL made its first investment of Rs 400 million in the company.
2008: 1st comprehensive cancer care centre in Jharkhand.
2009: One of the first centres in India to introduce CyberKnife technology.
2009: HCG Hubli, 1st centre in North Karnataka to introduce IGRT technology.
2009: Amalgamation of Triesta Sciences (India) Private Limited and Triesta Sciences Inc. with the company.
2010: IL&FS Trust Company Limited a/c MPEF, through its scheme India Build Out Fund I and MAT made its first investment of Rs 312 million in the company.
2011: HCG Ahmedabad, 1st privately owned comprehensive cancer care centre in Gujarat.
2011: Amalgamation of BMORCL with the company.
2012: HCG Chennai, 1st centre to use revolutionary FFF technology.
2013: HCG Cuttack, 1st comprehensive oncology centre in Odisha.
2013: Entered into the fertility business through acquisition of 50.10% stake in BACC Healthcare.
2016: Listed on BSE and NSE
2016: 1st centre to introduce Tomotherapy-H in India.
2015: HCG Regency became its subsidiary.
2015: Amalgamation of HCG Vijay with the company.
2017: First Indian company to setup a cancer centre in Africa.
2018: HCG Kolkata to launch 1st Radixact in India
2019: 1st Cyberknife in entire Western India
2020: 1st Digital PET CT in India
2021: Acquisition of Suchirayu
2022: 1st Centre to introduce Elekta Versa HD in the sub-saharan Africa
2023: 1st Centre to introduce varian ethos therapy, an AI driven holistic solution of radiation therapy in India
2023: Weaving a new era of cancer care in Indore. HCG launches a Comprehensive Cancer Centre in Indore, Madhya Pradesh.
2024: Acquisition of cancer centre at Indore.
2025: Acquisition of cancer centre (M G Hospital) at Vizag.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Healthcare Global Enterprises Ltd (HCG) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

HealthcareGlobal Share Price